home / stock / anpcy / anpcy short
Short Information | Angle Plc Surrey ADR (OTCMKTS:ANPCY)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 8,301 |
Total Actual Volume | 20,667 |
Short Trends | |
---|---|
Cover Days | 9 |
Short Days | 8 |
No Change Days | 3 |
Averages | |
---|---|
Average Short Volume | 415 |
Average Short Percentage | 47.70% |
Is there a ANPCY Short Squeeze or Breakout about to happen?
See the ANPCY Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-16-2024 | $2.73 | $1.92 | $2.91 | $1.92 | 3,107 | 990 | 31.86% |
02-12-2024 | $0 | $1.86 | $0 | $0 | 4 | 2 | 50% |
02-01-2024 | $2.4 | $1.86 | $2.52 | $1.86 | 5,329 | 2,408 | 45.19% |
01-29-2024 | $1.81 | $2.4 | $2.4 | $1.81 | 1,129 | 100 | 8.86% |
01-23-2024 | $2.41 | $2.41 | $2.41 | $2.41 | 572 | 524 | 91.61% |
01-22-2024 | $0 | $2.82 | $0 | $0 | 1,070 | 41 | 3.83% |
01-19-2024 | $2.73 | $2.82 | $2.82 | $2.73 | 1,028 | 761 | 74.03% |
01-17-2024 | $0 | $2.6404 | $0 | $0 | 69 | 61 | 88.41% |
01-16-2024 | $2.17 | $2.6404 | $2.6404 | $2.17 | 256 | 100 | 39.06% |
01-12-2024 | $2.48 | $2.48 | $2.48 | $2.48 | 956 | 889 | 92.99% |
01-11-2024 | $2.5 | $2.79 | $2.79 | $2.5 | 874 | 630 | 72.08% |
01-05-2024 | $3.96 | $3.25 | $3.96 | $3.25 | 3,544 | 827 | 23.34% |
12-22-2023 | $1.46 | $1.46 | $1.46 | $1.46 | 101 | 1 | 0.99% |
12-15-2023 | $1.21 | $1.63 | $1.63 | $1.21 | 375 | 150 | 40% |
12-05-2023 | $1.32 | $1.32 | $1.32 | $1.32 | 1,167 | 300 | 25.71% |
11-15-2023 | $0 | $1.21 | $0 | $0 | 1 | 1 | 100% |
10-27-2023 | $1.59 | $1.28 | $1.64 | $1.28 | 686 | 212 | 30.9% |
10-26-2023 | $0 | $1.52 | $0 | $0 | 76 | 3 | 3.95% |
10-25-2023 | $0 | $1.52 | $0 | $0 | 32 | 10 | 31.25% |
10-24-2023 | $1.52 | $1.52 | $1.52 | $1.52 | 291 | 291 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions...
ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutio...
Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circula...